Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mTOR Inhibitor PK/PD in Older Adults
NCT06727305Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sirolimus and everolimus in aging (6 arms), sponsored by UT Southwestern Medical Center. Primary endpoints: Maximum Plasma Concentration at 24 hours, Trough Plasma Concentration at 24 hours and 8 more. Started May 2026; status: recruiting.
02
Drugs
sirolimuseverolimus
03
Conditions
aging
Beyond the preview
Go deeper on NCT06727305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727305.